GLYN345

GLYN345 is a preclinical small molecule drug candidate being developed through a collaboration between NeuroBio.ai and Galyan Bio. It is primarily targeted toward the treatment of Parkinson's disease and the promotion of longevity. The compound was identified using NeuroBio.ai's AI-driven discovery platform in conjunction with Galyan Bio's expertise in neurodegenerative disease chemistry. While specific mechanistic details are often proprietary in early stages, Galyan Bio's platform focuses on sirtuin modulation, specifically SIRT2 inhibition, which has shown potential in reducing proteotoxicity and neuroinflammation associated with alpha-synuclein aggregation in Parkinson's models. The program is currently in the preclinical in vivo stage of development.